It sure was.
If you refer to page 15 of the company presentation, you'll note that Phylogica's peptide 1746 is highlighted for their vaccine program and that the company mentions that their FPP-peptide vaccine has the potential to synergize with existing immunotherapies. Note, that was using their first generation CPPs. Second generation CPPs is what my attention is on next. Have a read of this article re vaccines and immunotherapy to get a better understanding of how Phylogica could potentially play a role in this exciting field.
Hope this helps.
Tony
Ann: First Competitive Read Out - Peptide Vaccine, page-17
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
-0.005(4.55%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.5¢ | $99.01K | 931.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1170606 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 1088634 | 9 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |